Growth hormone medicine or increasing the death risk Three pharmacy giants are investigated

Growth hormone medicine or increasing the death risk Three pharmacy giants are investigated
According to sound " begging the wide news " of China, the European medicines administration bureau announced a few days ago, begin to examine the security of the growth hormone medicine to sell on the market of European Union. French medicine regulator is observed to discover, taking this kind of medicine may increase the death risk. The relevant medicine coming to the company, Swiss Novartis Company in American Pfizer pharmacy Co., Ltd., U.S.A. gift will be examined.
The European medicines administration bureau explains, the reason why examine the growth hormone medicine, because the person that the French medicines regulator took this kind of medicine to Childhood has launched the studying of long-term epidemiology, found finally the mortality of this part of crowds was a bit high. European medicines administration bureau says in the statement, the result of study reveals, the death risk of the drug therapy recipient of growth hormone is higher than that of common people, it seems to increase and increase with the using medicine amount that this kind is dangerous. But European medicines administration bureau admits, study yet enough to prove certain mortality on the high side using between the the medicine having inevitable connectioning according to the intersection of French and the intersection of medicine and observation of regulator only, need more investigations and could be confirmed.
The intersection of medicines and administration bureau claim, examine decision on the same day in European, Pfizer drugmaker announce against lung artery hypertension the intersection of medicine and Thelin withdraw market too, the reason is that this kind of medicine may cause the liver of the mortality to damage. Pfizer's pharmacy says voluntarily that will resist and press medicine Thelin to withdraw from European Union, Canada, Australian market, suspend all clinical research involved in this medicine at the same time.
Pfizer's pharmacy says in the statement, discover newly, Thelin may relate to the fact that the fatal liver is damaged, seeing that pulse and artery hypertension have other available therapeutic ways, Pfizer asserts for lung artery hypertension patients, it is that the fraud is greater than the profit to take Thelin. (reporter one would rather add)
|